Tenax Therapeutics soars on U.S. patent for pulmonary hypertension drug

Tenax Therapeutics

02/02/2023 12:14

** Shares of Tenax Therapeutics  TENX.O  soar 172% to $4.60
premarket 
    ** Says co granted U.S. patent, covering use of its
experimental intravenous drug, levosimendan, for the treatment
of pulmonary hypertension associated with a type of heart
failure
    ** Patent expected to last until 2040 - TENX
    ** There are currently no FDA approved treatments for
pulmonary hypertension with heart failure and preserved ejection
fraction, co adds
    ** Up to Wednesday's close, stock fell 89% in past 12 months
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))